ライフサイエンスコーパス: VAS

1 VAS for pain improved from 6.5 preoperatively to 4.2 (p<

2 VAS perception and anxiety scores did not change on firs

3 VAS was independently associated with MSNA burst frequen

4 VAS, K-L, and KOOS all significantly separated the OA an

5 = 0.04], VAS work satisfaction [P < 0.001], VAS work performance [P = 0.01]).

6 ta across the two diagnostic groups (p = .01 VAS, p = .02 HDRS-17).

7 d over 1 year (PCS p = 0.02; EQ-5D p = 0.02; VAS p = 0.01; SF-6D p = 0.03), becoming similar to age-a

8 surement Scales II pain subscale (P = 0.03), VAS pain (P = 0.007), EuroQol Index (P = 0.02), EuroQol

9 ) and most work outcomes (RA WIS [P = 0.04], VAS work satisfaction [P < 0.001], VAS work performance

10 baseline first-hour cough frequency (CF(1)), VAS, and LCQ to identify low CF(24) was assessed.

11 CF(24), VAS, and LCQ are responsive outcome tools for the assess

12 was improvement of at least 30 mm in 2 of 4 VASs by week 24.

13 as a greater than 35% LSAS reduction and 50% VAS-Anxiety reduction.

14 , pain, and anxiety), as well as lower EQ-5D VAS and EQ-5D index scores.

15 001) and a lower EQ-5D index value and EQ-5D VAS value (P < 0.001) compared to those with asthma only

16 vs 2 [IQR, 0-3] for promethazine [P = .81], VAS [0-10 scale] for nausea, 2 [IQR, 1-5] vs 2 [IQR, 1-4

17 for extracranial (91%) and intracranial (9%) VAS from 1995 to 2006.

18 of the 45 patients achieved and maintained a VAS score of 0 during the 3-year observation period.

19 that each patient experienced, also using a VAS.

20 dary efficacy end points included additional VAS items (burning/stinging, itching, foreign body sensa

21 P < 0.05) such that glucose-to-ileum altered VAS-rated fullness, satisfaction, and thoughts of food c

22 the overall feeling of sickness at altitude (VAS[O]; various thresholds), Acute Mountain Sickness-Cer

23 lcoxon signed-rank test z=2.24, p=0.025) and VAS (88.89% response ketamine vs 52.94% response placebo

24 re was a significant reduction in CF(24) and VAS, and improvement in LCQ, from visits 1-3.

25 ttern of change remained for PCS, EQ-5D, and VAS (p < 0.05).

26 creased operator experience (PCS, EQ-5D, and VAS p < 0.05) were independent predictors of a greater i

27 s (difference, 32.4; 95% CI, 24.9-39.8), and VAS satisfaction (difference, 33.2; 95% CI, 25.4-41.0) s

28 Scores on the BDI and VAS for breathing were highly correlated (r = -0.61).

29 ith more breathlessness (measured by BDI and VAS for breathing) and more abnormal physiologic measure

30 orrelation between VAS-global calculated and VAS-work (Rho=0.83, P<0.00001, Spearman's rank test).

31 ere assayed and correlated with clinical and VAS information in 40 patients.

32 h a decrease of 51-60% in TPs, FIQ, HAQ, and VAS scales, and in the number of prescribed drugs, accom

33 The smallest changes in CF(24), LCQ, and VAS that subjects perceived important were 54%, 2- and 1

34 e, all patients had poor Quality of Life and VAS scores, a high number of TPs and drug prescriptions,

35 ibutes to this process by regulating OSK and VAS localization.

36 The mean ItchyQoL total score and VAS symptom score were significantly improved in the rup

37 ng the m-ARIA, significantly higher T4SS and VAS scores were obtained when comparing severe with mode

38 ients recorded higher perception and anxiety VAS scores than patients undergoing surgery for the thir

39 tis VAS (R(2) = 0.53, P = 0.0008), arthritis VAS (R(2) = 0.53, P = 0.006), pulmonary VAS (R(2) = 0.69

40 VAS (r(s) = 0.36, P = 0.002), and arthritis VAS (r(s) = 0.40, P = 0.001).

41 ment (P=0.046 for treatment arm and baseline VAS interaction).

42 e primary end point was change from baseline VAS score in 24-hour pain averaged over days 14-18.

43 as outcomes in patients with higher baseline VAS scores were similar regardless of treatment assignme

44 No such difference was seen if baseline VAS was >/=55 (70+/-7% versus 75+/-9%; P=0.79).

45 ersus optimal medical management if baseline VAS was <55, whereas outcomes in patients with higher ba

46 Among patients with baseline VAS<55, survival on original treatment was lower for opt

47 There was a significant correlation between VAS-global calculated and VAS-work (Rho=0.83, P<0.00001,

48 there was a significant correlation between VAS-work and WPAI:AS (Rho=0.53, P<0.0001).

49 No correlations between VAS score and laboratory inflammatory markers were ident

50 ed significant negative correlations between VAS score and MR imaging bowel wall arterial phase enhan

51 The correlations between VAS, EQ-5D and LupusQoL were significant; relative good

52 Fifty-seven patients (54%) had bilateral VAS, 71 patients (68%) had concomitant carotid disease,

53 roup, m-YPAS positively correlated with both VAS and FLACC (P = 0.000 and 0.002, respectively).

54 nts of musical sound quality, as assessed by VAS.

55 rovement in joint function, as determined by VAS scores, at 6 weeks, as compared with inaccurate inje

56 sis; reliability ratios were used to compare VAS and UCEIS scores.

57 evalence of chronic disabling complications (VAS score >30 for pain/numbness/groin discomfort) at 12

58 Conclusion VAS assessment of HRQOL changes over time in response to

59 mptoms of allergic rhinitis were controlled (VAS-global <20) in approximately 60% of the days.

60 y healthy subjects with URTI completed cough VAS, Leicester Cough Questionnaire (LCQ-acute), and CF(2

61 visual analogue scale area under the curve (VAS AUC) to day 5 and the proportion of patients with mo

62 bly related to factors such as demographics, VAS score, disease classification, and SF-36 PCS and MCS

63 vs. first dose of doxazosin: mean difference VAS -10 mm (95% CI -18 to -2) P = 0.02, blockage -0.7 (9

64 Each user filled 4 different VAS measuring overall, nasal, ocular, and asthma symptom

65 TDS, age, and severity of Raynaud's disease VAS.

66 with recovery between first and last doses: VAS 15 mm (95% CI 4-25) P = 0.009, blockage 1.1 (95% CI

67 T-G (and all subscales), EQ-5D Index, and EQ-VAS were all significantly favorable for sunitinib (P <

68 g a generic instrument (EuroQoL EQ-5D and EQ-VAS).

69 Mean changes from baseline EQ-VAS scores were better for IS than for CS at four months

70 EQ-5D Index) and its visual analog scale (EQ-VAS).

71 Life questionnaire - Visual Analog Score [EQ-VAS]), levels of antioxidants, use of opiates, and adver

72 changes in global, muscle, and extramuscular VAS scores (P < 0.05).

73 Fatigue VAS scores were significantly lower in the CBTH group at

74 romyalgia Impact Questionnaire (FIQ) and FIQ VAS scores for individual symptoms (fatigue, poor sleep,

75 ry outcome measure (area under the curve for VAS scores -20 in the TDF group versus -14.6 in the plac

76 erall significant differences were found for VAS score (warm saline group: baseline=8.9+/-0.6, 1 mont

77 Testing characteristics were similar for VAS(O), AMS-C, and CFS vs a score of 5 or greater on the

78 30-mm decreases in at least two of the four VAS scores was higher in the rituximab group at week 6 (

79 Accordingly, we have named these genes "VAS" genes for virulence-associated secretion, and we pr

80 lmonary VAS (R(2) = 0.69, P = 0.005), global VAS (R(2) = 0.63, P = 0.002), and global MITAX (R(2) = 0

81 I -3.82, -0.49; P = 0.01]), physician global VAS (-1.71 cm [95% CI -2.75, -0.66; P = 0.002]), chair s

82 kload was greater in the interruption group (VAS score, 4.22 vs 3.80; mean difference, 0.41; 95% CI,

83 al tDCS group, compared with the sham group, VAS ratings for hunger and the urge to eat declined sign

84 r = 0.788; US, r = 0.811) and global health VAS (NL, r = -0.517; US, r = -0.593) was good.

85 */G men 12 months after the disc herniation (VAS, p = 0.043, one-way ANOVA; p = 0.035, Tukey HSD).

86 th more restricted joint movement and higher VAS.

87 survival and survival with acceptable hrQoL (VAS>/=60).

88 ent and over 50% had severe work impairment (VAS-work >50).

89 min 500 ng/100 microL per linear cm improved VAS score by 16.12 mm (95% CI 10.61-21.63).

90 The patient reported pain of 8-10 in VAS (Visual Analogue Scale) and had an ODI (Oswestry Dis

91 Change in VAS breathlessness did not differ between active treatme

92 .819) for hospital admission and a change in VAS breathlessness of -2.6 mm (-7.0 to 1.8; p=0.253) com

93 .083) for hospital admission and a change in VAS breathlessness of 2.6 mm (-1.6 to 6.8; p=0.231) comp

94 .57, P = .0032) as well as between change in VAS score and change in bowel wall enhancement in the ar

95 een subject and parent or guardian change in VAS score between baseline and follow-up (rho = 0.71; P

96 active treatments and control, but change in VAS was greater for patients in the intravenous MgSO(4)

97 103 (integrin alphaEbeta7) expressing DCs in VAS versus VAD piglets postchallenge, indicating that VA

98 There was no statistical difference in VAS for nausea, but it was numerically superior with apr

99 group at 6 months, with a mean difference in VAS score between the IPC group and the talc group of -1

100 The mean +/- SD difference in VAS was 51.6 +/- 28.11 mm in favor of the anesthetic gel

101 Differences between CTG and FGG groups in VAS pain scores at 3 days did not reach statistical sign

102 An improvement of at least 30 mm in VAS fatigue score was more common with rituximab at week

103 uce the severity of nausea when reduction in VAS score was used as the primary outcome.

104 endoscopic nasal polyp score, all individual VAS symptom scores, and Sino-Nasal Outcome Test patient-

105 nasal polyp score, improvement in individual VAS symptoms (rhinorrhea, mucus in throat, nasal blockag

106 the nonselective NAD(P)H oxidase inhibitors VAS-2870, AEBSF, and the Nox1 NAD(P)H oxidase-specific i

107 Most patients showed low VAS pain scores for both probes.

108 Mean VAS change from pre- to post-treatment did not differ si

109 Mean VAS score before the procedure was 7.75 of 10.

110 oup (n = 54) vs the 24F group (n = 56) (mean VAS score, 22.0 mm vs 26.8 mm; adjusted difference, -6.0

111 difference in the first 42 days with a mean VAS dyspnea score of 24.7 in the IPC group (95% CI, 19.3

112 Smooth-bordered lesions received a mean VAS score of 1.76, corresponding to a fair response on a

113 Irregularly bordered lesions received a mean VAS score of 3.67, corresponding to an excellent respons

114 144) were not significantly different (mean VAS score, 23.8 mm vs 22.1 mm; adjusted difference, -1.5

115 rative pain was less in the SPLC-group (mean VAS 1 vs 2, p = 0.005), there were no differences in com

116 In both groups, mean VAS and EHP30 scores improved significantly and remained

117 The pre- and posttreatment mean VAS scores significantly differed (7.9 +/- 1.4 and 0.0 +

118 The mean VAS decreased significantly among those taking the place

119 Similarly, median VAS scores for the degree to which pain interfered with

120 Results The median VAS score was 47.5 (interquartile range [IQR]: 20.0-52.2

121 n in SC patients (26 +/- 4 mm vs 39 +/- 4 mm VAS, respectively, p = 0.012) but there were no signific

122 ing the pain intensity during the 12 months (VAS, p = 0.002; McGill, p = 0.021; ODI, p = 0.205, repea

123 K levels (R(2) = 0.65, P = 0.0002), myositis VAS (R(2) = 0.53, P = 0.0008), arthritis VAS (R(2) = 0.5

124 CK levels (r(s) = 0.38, P = 0.002), myositis VAS (r(s) = 0.36, P = 0.002), and arthritis VAS (r(s) =

125 ergic symptoms (VAS-global measured), nasal (VAS-nasal), ocular (VAS-ocular) and asthma symptoms (VAS

126 Nausea VAS scores correlated positively with plasma vasopressin

127 t improvement in obsessions (measured by OCD-VAS) during the infusion compared with subjects receivin

128 The OCD visual analog scale (OCD-VAS) and the Yale-Brown Obsessive-Compulsive Scale (Y-BO

129 global measured), nasal (VAS-nasal), ocular (VAS-ocular) and asthma symptoms (VAS-asthma) as well as

130 P-1 and PYY secretion, suppressed aspects of VAS-rated appetite, and decreased ad libitum EI at a sub

131 A total of 1136 users filled in 5818 days of VAS-work.

132 There were no significant differences of VAS scores for perception of discomfort for periodontal

133 onal health and pain was a good predictor of VAS.

134 However, using an arbitrary threshold of VAS > or =40 mm to indicate significant pain, some patie

135 scaled according to VAS or transformation of VAS.

136 AS and TTO utilities and a transformation of VAS.

137 aim of this study was to validate the use of VAS in the MASK-rhinitis (MACVIA-ARIA Sentinel NetworK f

138 ects were stratified into quartiles based on VAS nausea scores, with the upper and lower quartiles co

139 is currently in phase 2 clinical trials, or VAS-2870 attenuated NLRP3 inflammasome activation.

140 ine cell fate is specified by localized OSK, VAS and other components in the pole plasm of the Drosop

141 The overall VAS score for abnormality had high agreement and reliabi

142 e likelihood of clinically significant pain (VAS rating, >/=5.4) was significantly greater with 30-ga

143 nce by repeated comparisons of the patients' VAS pain ratings with independent ratings by the residen

144 al signs (objective SCORAD), symptoms (POEM, VAS pruritus, VAS sleeping problems) and previous treatm

145 CI, -33.1 to -50.2), and higher preoperative VAS preparedness (difference, 32.4; 95% CI, 24.9-39.8),

146 In addition, VR led to lower preoperative VAS stress score (difference, -41.7; 95% CI, -33.1 to -5

147 ctive SCORAD), symptoms (POEM, VAS pruritus, VAS sleeping problems) and previous treatment of AD were

148 itis VAS (R(2) = 0.53, P = 0.006), pulmonary VAS (R(2) = 0.69, P = 0.005), global VAS (R(2) = 0.63, P

149 no significant differences between repeated VAS scores for pain perception (P = 0.91) or anxiety (P

150 nificant correlations between child-reported VAS score and (a) the degree of bowel wall enhancement i

151 Differences between patients' and residents' VAS scores gradually became smaller over time for two of

152 The MASK-rhinitis VAS is a reliable and valid tool to assess allergic cont

153 vity, and acceptability of the MASK-Rhinitis VAS.

154 orative stimuli using a visual analog scale (VAS) and a Schiff scale.

155 ase Activity Assessment Visual Analog Scale (VAS) and the Myositis Intention-to-Treat Index (MITAX) c

156 y outcome was the EQ-5D visual analog scale (VAS) at 6 months.

157 th the TTO method and a visual analog scale (VAS) by using a questionnaire administered by means of a

158 outcome was grade in a visual analog scale (VAS) consisting of 4 levels of treatment response: poor

159 Pain assessment on the visual analog scale (VAS) during blue light illumination was not significantl

160 spnea index (BDI) and a visual analog scale (VAS) for breathing, were divided at the median.

161 Pain was measured on a visual analog scale (VAS) from 0 to 10 before and immediately after the proce

162 leted daily 100-mm line visual analog scale (VAS) of dyspnea over 42 days after undergoing the interv

163 tient-reported 0-to-100 visual analog scale (VAS) of nausea severity.

164 ported pain rating on a visual analog scale (VAS) on either side of the face and arms and the proport

165 The median visual analog scale (VAS) pain score (scale, 0-10) decreased from 8 before tr

166 A visual analog scale (VAS) score for pain was used to assess changes in sympto

167 tcome measures were the visual analog scale (VAS) score for pain, tender point count, and total myalg

168 truments, including the visual analog scale (VAS) score, which quantifies the overall feeling of sick

169 asal polyposis severity visual analog scale (VAS) score.

170 ptions were measured by visual analog scale (VAS) scores and by interview of patients (N = 102) under

171 uscle and extramuscular visual analog scale (VAS) scores correlated positively with changes in IFN ge

172 Raynaud's disease visual analog scale (VAS) scores, lung function, the number of organ systems

173 nts from probing, using visual analog scale (VAS) to record pain.

174 A visual analog scale (VAS) was used by the examiner and subject to assess the

175 /or pain according to a visual analog scale (VAS), a health-related quality of life score (Skindex-29

176 Pain was recorded on a visual analog scale (VAS), and function was assessed using the Western Ontari

177 measurement based on a visual analog scale (VAS), and patient-stated preference after the second stu

178 ability were rated on a visual analog scale (VAS), by McGill Sensory Questionnaire and by Oswestry Di

179 tandard gamble (SG) and visual analog scale (VAS), in SLE patients.

180 toms of nose and eye by visual analog scale (VAS), quality of life (QOL) scores by Japanese rhino-con

181 toms of nose and eye by visual analog scale (VAS), quality of life (QOL) scores by Japanese rhino-con

182 toms of nose and eye by visual analog scale (VAS), symptom scores and combined symptom-medication sco

183 ately afterward using a visual analog scale (VAS), the 17-item Hamilton Depression Rating Scale (HDRS

184 was assessed by using a visual analog scale (VAS).

185 in was assessed using a visual analog scale (VAS).

186 ribe their pain using a visual analog scale (VAS).

187 te was evaluated with a visual analog scale (VAS).

188 was noted according to visual analog scale (VAS).

189 f-reported anxiety on a visual analog scale (VAS-Anxiety).

190 0.001]), patient global visual analog scale (VAS; -2.15 cm [95% CI -3.82, -0.49; P = 0.01]), physicia

191 ty was assessed using a visual analog scale (VAS; range 0-150).

192 symptoms, measured on a visual-analog-scale (VAS), and secondary outcome was eradication of D. fragil

193 Nasal visual analogue scale (VAS) and blockage scores were worse between baseline vs.

194 ms were assessed by a visual analogue scale (VAS) and symptom specific quality of life questionnaire

195 outcome measures were visual analogue scale (VAS) assessments for "pain," "numbness," and "groin disc

196 ian score on a 100 mm visual analogue scale (VAS) by 5 mm (range -2 to 14; p=0.001) at month 6 and 8

197 ui torticollis scale, Visual Analogue Scale (VAS) for pain and Fugl-Meyer scale for QoL.

198 measured on a 100 mm visual analogue scale (VAS) in the 2 h after initiation of treatment.

199 Visual Analogue Scale (VAS) is a validated tool to assess control in allergic r

200 scale, global health visual analogue scale (VAS) of EQ-5D, and liver volume.

201 Weekly visual analogue scale (VAS) scores for myalgia and specific symptoms (VAS myalg

202 POS control criteria, visual analogue scale (VAS) scores for total and individual sinonasal symptoms,

203 IS were scored with a visual analogue scale (VAS) to assess overall severity.

204 questionnaires and a visual analogue scale (VAS) were used for the assessment of anxiety and nausea.

205 ted pleasantness on a visual analogue scale (VAS) when we stroked with a soft brush with speeds from

206 f eye dryness using a visual analogue scale (VAS), and noninvasive tear film breakup time (NITBUT).

207 rotein (hs-CRP) and a visual analogue scale (VAS), respectively.

208 d-type Elstar using a visual analogue scale (VAS).

209 IA severity items and visual analogue scale (VAS).

210 Qol questionnaire and visual analogue scale (VAS).

211 i) to follow-up using visual analogue scale (VAS).

212 rhinitis assessed by visual analogue scale (VAS).

213 in place (0- to 100-mm visual analog scale [VAS] 4 times/d; superiority comparison) and pleurodesis

214 an metoclopramide (mean visual analog scale [VAS] score, 4.1 [SD, 2.9] for ondansetron vs 5.7 [SD, 2.

215 n the pain score (10-cm visual analog scale [VAS]) at 14 weeks.

216 n (>/=50 mm on a 100 mm visual analog scale [VAS]) received 375 mg NTG 0.4% (1.5 mg active ingredient

217 ) and the EQ-5D (with a visual analog scale [VAS])-were completed at baseline, 30 days, 6 months, and

218 workload (on a 10-point visual analog scale [VAS]).

219 ent of HRQOL utilities (visual analog scale [VAS], time trade-off [TTO], and standard gamble [SG]), M

220 ain (measured using a visual analogue scale [VAS]) and length of ICU stay.

221 re (EDS) >/=40 (0-100 visual analogue scale [VAS]), and history of artificial tear use within 30 days

222 ing were measured with visual analog scales (VAS) and a Drug Effects Questionnaire.

223 Visual analog scales (VAS) for assessment of function, pain, and stiffness of

224 RA WIS; EuroQol Index; visual analog scales (VAS) for pain, work satisfaction, and work performance;

225 aded 100-mm horizontal visual analog scales (VAS) representing right and left sides of the mouth.

226 Therapy Fatigue Scale, visual analog scales (VAS), the Profile of Mood States, and the RA-specific Mu

227 ing, and cooling using visual analog scales (VAS).

228 fe Questionnaire and visual analogue scales (VAS) for dysmenorrhea, chronic pelvic pain, and deep dys

229 alth Survey (SF-36), Visual Analogue Scales (VAS) for gastrointestinal complaints, pain and tiredness

230 ects data from daily visual analogue scales (VAS) for overall allergic symptoms (VAS-global measured)

231 d symptoms and using visual analogue scales (VAS) for pain, tingling and discomfort.

232 pants completed four Visual Analogue Scales (VAS) to assess musical sound quality.

233 S) assessed by daily visual analogue scales (VAS).

234 sessed with the use of visual analog scales (VASs), blood samples collected, and ad libitum energy in

235 -Fatigue subscale and Visual Analog Scales (VASs; Fatigue and Muscle Weakness).

236 y measure using a 10-cm visual analog score (VAS 0-10).

237 ns were monitored using visual analog score (VAS) 12 weeks after onset of fever in 130 patients.

238 >/=8 years completed a visual analog score (VAS) for pain.

239 by interviews and by a visual analog score (VAS) of pruritus recorded every hour while patients were

240 OOS) and knee pain by visual analogue score (VAS).

241 4 scale) in study eye, eye discomfort score (VAS), total corneal staining score in the study eye, and

242 om baseline to day 84, in eye dryness score (VAS, both eyes) and inferior corneal fluorescein stainin

243 el was 23.5 +/- 16.8 mm, and the mean +/- SD VAS for the placebo gel was 23.5 +/- 14.6 mm.

244 The mean +/- SD VAS for the test gel was 23.5 +/- 16.8 mm, and the mean

245 ore painful with 30-gauge needles (mean [SD] VAS ratings for the face, 4.16 [2.55] vs 3.41 [2.31], P

246 rying cognate variable activating sequences (VAS) in distinct neighbouring cell types of the Drosophi

247 cant improvement in nasal polyposis severity VAS score, endoscopic nasal polyp score, all individual

248 included change in nasal polyposis severity VAS score, endoscopic nasal polyp score, improvement in

249 essed and nonvocoded virtual acoustic space (VAS) stimuli.

250 We used virtual auditory space (VAS) methods for sounds at various distances in anechoic

251 o in the VAS myalgia score, symptom-specific VAS score, pain interference score, and pain severity sc

252 toms (VAS myalgia score and symptom-specific VAS score, respectively), pain interference scores, and

253 y for symptomatic vertebral artery stenosis (VAS).

254 e the midline in the ventral acoustic stria (VAS) are primarily located in the ventral cochlear nucle

255 The analysis of the investigator and subject VAS assessments indicates that the test treatment was su

256 The examiner and subject VASs were statistically significantly different from bas

257 The VAD and vitamin A-sufficient (VAS) Gn pigs were vaccinated with attenuated HRV (AttHRV

258 It supports VAS for symptom assessment and placebo-based analysis as

259 Symptomatic VAS carries with it a 5-year 30% to 35% risk of stroke.

260 experienced hands, stenting for symptomatic VAS can be accomplished with a very high success rate (1

261 scales (VAS) for overall allergic symptoms (VAS-global measured), nasal (VAS-nasal), ocular (VAS-ocu

262 l), ocular (VAS-ocular) and asthma symptoms (VAS-asthma) as well as work (VAS-work).

263 S) scores for myalgia and specific symptoms (VAS myalgia score and symptom-specific VAS score, respec

264 Since the number of combinatorial TALE-VAS pairs is virtually unlimited, this platform provides

265 The VAS pain scores showed favorable anesthetic efficacy of

266 The VAS scores for the experimental group decreased during t

267 sm and NITBUT (P = 0.013, d = 1.08); and the VAS and DEQ-5 (P = 0.034, d = 0.58).

268 Both the EQ-5D index and the VAS score declined in a stepwise fashion with increasing

269 .6 [95% CI, 7.9 to 51.2] [P = .009]) and the VAS score for pruritus (MD, 4.6 [95% CI, 1.5 to 7.7] [P

270 correlation between TRPV1 expression and the VAS scores for pain, tingling or discomfort.

271 baseline for both treatment groups, and the VAS was superior for the test sites over the placebo.

272 ensitivity when users (n = 521) answered the VAS twice in less than 3 hours.

273 All consecutive users who completed the VAS-work from 1 June to 31 October 2016 were included in

274 Thus, the genes encoding the VAS-related, type VI secretion system likely play an imp

275 cially the distribution of responses for the VAS.

276 Serelaxin improved the VAS AUC primary dyspnoea endpoint (448 mm x h, 95% CI 12

277 or DCC, robo-1, and robo-2, and axons in the VAS are immunoreactive for DCC.

278 were seen between statin and placebo in the VAS myalgia score, symptom-specific VAS score, pain inte

279 rimary outcome measure (46% reduction in the VAS score in the aprepitant group vs 40% reduction in th

280 x Treatment: F9,115=2.6, p=0.01) but not the VAS-Anxiety (Time x Treatment: F10,141=0.4, p=0.95).

281 ticipants who self-reported more pain on the VAS scale produced higher levels of IL6 compared with th

282 ity in evaluation of overall severity on the VAS when assessing the endoscopic severity of UC and was

283 stic subgroups for our primary outcomes, the VAS and the HDRS-17.

284 After UV-A1 phototherapy, the VAS score for burning and/or pain (MD, 3.2 [95% CI, 0.7

285 further validation in patients with RA, the VAS requires standardization, and the MAF would benefit

286 These findings suggested that the VAS and EQ-5D might be valid and reliable measures to as

287 The primary outcome was the VAS myalgia score (range, 0 to 100 mm).

288 cording to TTO than when scaled according to VAS or transformation of VAS.

289 levels of control corresponded to mean total VAS, SNOT-22 and SF-36 scores.

290 Subsequently, the residents compared the two VAS ratings and discussed differences in ratings with th

291 Patients' interaction (measured using VAS) was improved with dexmedetomidine (estimated score

292 ha levels were induced in control VAD versus VAS piglet sera at postchallenge day 2.

293 Muscle Weakness VAS scores were significantly lower in the CBTH group at

294 For the FGG group, 3-week VAS pain scores were less than the 3-day ones (P <0.01).

295 nd arms and the proportion of patients whose VAS ratings corresponded with more than moderate (ie, cl

296 Esthetics outcome was assessed with VAS and the Questionnaire of Oral Esthetic Satisfaction.

297 substantially postchallenge as compared with VAS pigs.

298 No association was identified with VAS stress score (difference, -1.6; 95% CI, -13.4 to 10.

299 times were adjusted for quality of life with VAS and TTO utilities and a transformation of VAS.

300 sthma symptoms (VAS-asthma) as well as work (VAS-work).